SWK — Investor Presentation (May 2019)
44 slides from SWK's investor presentation, May 21, 2019
Slide 1: Collaborative Approach to Life Science Financing
Collaborative Approach to Life Science Financing
Slide 2: Forward-looking and Cautionary Statements
Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal securi
Slide 3: Corporate Overview
L. ASWK roines CORPORATE OVERVIEW
Slide 4: SWK Holdings Overview
SWK Holdings Overview SWK provides custom financing solutions for commercial - stage healthcare companies and royalty owners Deploys balance sheet capital into secured financing portfolio ̶ Market capitalization on May 15, 2019 was $129mm, 59% of March 31, 2019 stockholders equity of $219mm ̶ Repurc
Slide 5: Why Life Science Finance?
Why Life Science Finance? Achieve high current yield from investment in non - correlated assets ̶ Invest in royalty, revenue, equity & debt interests from healthcare companies, research institutions and inventors ̶ Structured debt: high coupon drives current yield and warrants provide equity upside;
Slide 6: Experienced Team
Experienced Team SWK’s investment professionals have extensive experience financing life science companies CEO Winston Black has been active in life science structured finance asset class since 2007 when he helped manage a multi - billion dollar healthcare portfolio for a large investment firm and h
Slide 7: Corporate Milestones
Corporate Milestones 7 Pre - 2014 2014 2015 2016 2017 2018 2019 • Predecessor Kana Software assets sold to Kay Technologies; $450mm+ NOLs remained at sale • Winston Black and Brett Pope hired to launch life science technology finance strategy • $113mm raised through private placement and rights offe
Slide 8: Value Creation Strategy
Value Creation Strategy Deploy balance sheet capital into secured financing portfolio ̶ $5mm to $20mm life science loan and royalty market sports attractive, low - to - mid teens yields ̶ SWK has established reputation as a go - to capital provider for this underserved market ̶ Majority of financing
Slide 9: Portfolio Overview: 1Q19
* GAAP value at March 31, 2019; does not include capital advances made subsequent to quarter end ** Private warrants carried at zero cost Portfolio Overview: 1Q19 9 • Income Producing Assets: $154.9mm • Finance Receivables: $154.4mm • Corporate Debt Securities: $0.5mm • Public Warrants: $3.1mm ** Po
Slide 10: SWK Key Statistics
SWK Key Statistics 10 * Defined as finance receivables, marketable investments and investment in unconsolidated entity less non - controlling interests ** During 2017 SWK incurred a $15.7mm provision for income taxes to reduce the carrying value of the deferred tax asset to account for a r eduction
Slide 11: SWK Targets Low- to Mid-Teens Effective Yields
SWK Targets Low - to - Mid Teens Effective Yields 1Q19 Effective Yield of 14.2% 11 * Includes non - accruals; excludes warrants ** Includes non - accruals; effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies , if all payment
Slide 12: SWK Employs a Lean Cost Structure
SWK Employs a Lean Cost Structure 12 SWK is internally managed and does not engage outside advisors to fulfill the investment function Management receives a fixed salary and participates in a bonus pool based on the Company’s annual pre - tax profit CORPORATE OVERVIEW 1.0% 1.5% 2.0% 2.5% $2.0 $3.0 $
Slide 13: Investment Process
L. ASWK roines INVESTMENT PROCESS
Slide 14: Underwriting Process Overview
Underwriting Process Overview Sourcing Initial Analysis and Screening Detailed Diligence Preliminary Term Submission Investment Committee Approval and Term Sheet Monitoring Legal Documentation 14 • Financing prospects are sourced via proprietary network and brokers • Initial diligence focuses on med
Slide 15: Sourcing
Sourcing SWK has a well - developed and diversified sourcing network ̶ SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $20mm financings The deals c
Slide 16: Proposals and Win Rate
Proposals and Win Rate In 2018 SWK evaluated approximately 80 financings * and submitted preliminary term proposals on 30 financings ̶ The 30 proposals represented $350mm of SWK capital and $444mm of total capital including partners In 2017 SWK evaluated approximately 69 financings * and submitted p
Slide 17: Diligence Process
Diligence Process SWK’s diligence process is anchored by the “four Cs” of credit analysis: Collateral, Character, Capacity, and Capital Collateral value is ascertained through analysis of medical and commercial need, market size, IP, and potential strategic buyers and historical transaction valuatio
Slide 18: Current Portfolio
L. ASWK roines CURRENT PORTFOLIO
Slide 19: 1Q19 Portfolio Overview
1Q19 Portfolio Overview 19 CURRENT PORTFOLIO Financing (Month Closed) Type Primary Product Product Marketer Funded Amount / Principal GAAP Value Coupon Rate Beleodaq ( 6/2018) Royalty Oncology treatment Acrotech $7.6mm $7.0mm N/A Besivance (4/2013) Royalty Ophthalmic antibiotic Bausch Health $6.0mm
Slide 20: 1Q19 Portfolio Overview
1Q19 Portfolio Overview 20 CURRENT PORTFOLIO Financing (Month Closed) Type Primary Product Product Marketer Funded Amount / Principal GAAP Value Coupon Rate Acerus Pharmaceuticals (10/2018) First Lien Men’s health Self / Aytu (U.S.) $9.0mm $8.3mm LIBOR+10.5% Aimmune Therapeutics, Inc. (2/2019) First
Slide 21: 1Q19 Portfolio Overview
1Q19 Portfolio Overview 21 CURRENT PORTFOLIO Financing (Month Closed) Type Primary Product Product Marketer Funded Amount / Principal GAAP Value Coupon Rate Harrow Health* (7/2017) First Lien Pharmacy Self $9.3mm $9.0mm LIBOR (1.5% floor;3.0% cap) +10.5% Keystone Dental (5/2016) First Lien Dental im
Slide 22: Realizations and Case Studies
REALIZATIONS AND CASE STUDIES
Slide 23: Portfolio Realizations
Portfolio Realizations SWK has exited fifteen financings for a total 1.2x CoC return and 19% weighted average IRR as of May 15, 2019 ̶ Twelve resulted in positive realizations with a cumulative 1.4x CoC and weighted average 31% IRR ̶ SynCardia position was sold to distressed private equity firm with
Slide 24: Portfolio Realizations to Strategic Buyers
Portfolio Realizations to Strategic Buyers Nine realizations to strategic buyers demonstrated a median 32% LTV of SWK’s original loan value Six of the nine businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology 24 REALIZATIONS AND CASE STUDIE
Slide 25: Historical Financing: Holmdel Pharmaceuticals, LP
Historical Financing: Holmdel Pharmaceuticals, LP In December 2012 SWK acquired a limited partnership interest in Holmdel Pharmaceuticals Holmdel subsequently acquired U.S. marketing rights to InnoPran XL, a non - selective beta blocker with dosing technology to coincide with the body’s natural circ
Slide 26: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth from expanded distribution, not price hikes Opiant is a publicly traded drug development company that receives a r
Slide 27: Historical Financing: Galil Medical
Historical Financing: Galil Medical Galil is a medical device company that delivers innovative cryotherapy solutions for tumor ablation In 2014, the privately - held company was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing c
Slide 28: Historical Financing: SynCardia
Historical Financing: SynCardia SynCardia manufactures and markets the only FDA - approved artificial heart SWK’s original thesis: ̶ Device approved in US and EU; positive efficacy in over 1,500 implants ̶ Device reimbursed at $125,000 in US and $70,000 outside the US ̶ Large and untapped market wit
Slide 29: Miscellaneous
L. ASWK roines MISCELLANEOUS
Slide 30: SWK Value Proposition to Partners
SWK Value Proposition to Partners SWK’s asset base and nimble structure position it to serve the sub - $20mm financing market ̶ Smaller companies often don’t have financial profile to qualify for traditional financing sources ̶ Companies in this niche often have few options outside of a dilutive equ
Slide 31: Financing Structures
Financing Structures Structured debt ̶ Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities ̶ Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage ̶ Provide working capital to support product commercializa
Slide 32: Illustration: Royalty Stream Creation
Illustration: Royalty Stream Creation Small Biotech enters into marketing collaboration with Big Pharma 1. Small Biotech licenses marketing rights of Drug A to Big Pharma in exchange for upfront payment and a 10% royalty stream 2. Big Pharma markets the drug and begins to pay a 10% royalty stream on
Slide 33: Biographies and Contact Information
BIOGRAPHIES AND CONTACT INFORMATION
Slide 34: Biographies: Winston Black, CEO
Biographies Winston Black, CEO Mr. Black was appointed CEO in January 2016. He joined SWK as Managing Director in May 2012 from PBS Capital Management, LLC, an investment management business investing in pharmaceutical royalties and healthcare equities that Mr. Black co - founded in 2009. Prior to P
Slide 35: Biographies: Jody Staggs, VP
Biographies Jody Staggs, VP Mr. Staggs joined SWK Holdings as a Senior Analyst in August 2015. Prior to joining SWK, he was Vice President of Investments at Annandale Capital. Prior to joining Annandale, he was the first employee at Alistair Capital, a Dallas - based hedge fund. He previously co - f
Slide 36: Biographies: Wynn Lemmons and Yvette Heinrichson
Biographies Wynn Lemmons, Analyst Mr. Lemmons joined SWK Holdings as an Analyst in January 2018. Prior to joining SWK, he was an Analyst at Oaklawn Investments , a Dallas - based investment company, working primarily on distressed credit and special situations. Prior to that, he performed equity res
Slide 37: Biographies – Board of Directors
Biographies – Board of Directors Michael D. Weinberg, Chairman of the Board Mr. Weinberg is Chief Operating Officer of Carlson Capital, L.P. Mr. Weinberg has served in various capacities with Carlson s inc e November 1999. Since April 2007, Mr. Weinberg has served as the managing member of BirdDog C
Slide 38: Biographies – Board of Directors
Biographies – Board of Directors Edward Stead Mr. Stead has served as a senior executive for various companies over an extensive business career. Mr. Stead began his caree r a s a lawyer at IBM from 1973 to 1985. He then served at Apple Computer, Inc. from 1987 until 1996, where he held titles up to
Slide 39: Contact Information
Contact Information Winston Black: ̶ Phone: 972.687.7251 ̶ Email: wblack@swkhold.com Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com Office address: ̶ 14755 Preston Road, Ste 105 Dallas, TX 75254 Website: www.swkhold.com 39 BIOGRAPHIES AND CONTACT INFO
Slide 40: Financial Overview
L. ASWK roines FINANCIAL OVERVIEW
Slide 41: Balance Sheets
Balance Sheets 41 FINANCIAL OVERVIEW $ in 000s Mar-19 Dec-18 Dec-17 Dec-16 ASSETS Cash and cash equivalents 39,183$ 20,227$ 30,557$ 32,182$ Accounts receivable 1,930 2,195 1,637 1,054 Finance receivables 154,410 166,610 151,995 126,366 Marketable investments 511 532 1,856 2,621 Investment in unconso
Slide 42: Income Statements
Income Statements 42 FINANCIAL OVERVIEW $ in 000s LTM Dec-18 Dec-17 Dec-16 Revenues Finance receivable interest income, including fees 28,552$ 25,978$ 26,877$ 15,747$ Marketable investments interest income - - - 92 Income related to investments in unconsolidated entities - - 10,530 6,219 Other 8 12
Slide 43: Cash Flow Statements
Cash Flow Statements 43 FINANCIAL OVERVIEW $ in 000s,* LTM Dec-18 Dec-17 Dec-16 Cash flows from operating activities: Consolidated net income $9,110 $6,195 $8,251 $32,041 Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entit
Slide 44: Reconciliation of Non-GAAP Adjusted Net Income
Reconciliation of Non - GAAP Adjusted Net Income Attributable to SWK Stockholders The table below eliminates provisions for income taxes, non - cash mark - to - market changes on warrant assets and SWK’s warrant liab ility, as well as, warrant - related debt issuance costs and stock compensation exp